HEALTH OF WOMAN. 2016.3(109):103–108 
 

Pharmacological profile of preparation Оfor in the aspect of rational antimicrobial therapy for mixed infections 
 

Mamchur V. I., Dronov S. N.

SІ «Dnipropetrovsk medical Academy Ministry of health of Ukraine» 
 

The review presents the analysis of pharmacological properties of a medicinal product Ofor is a fixed combination of 200 mg of ofloxacin and 500 mg of ornidazole with the criterion of «necessity and sufficiency» in relation to the choice of a rational antimicrobial therapy of mixed infections. It is shown that combination of оfloxacin with ornidazole most fully encompasses a broad range of pathogens mixed urogenital infections and is characterized by high efficiency and good tolerability in the treatment of patients with infectious-inflammatory diseases of the pelvic organs in gynecology, the treatment of demodecosis and acne in dermatology, mixed infections of the abdominal cavity and biliary tract, the respiratory system.

It is noted that the Ofor has high safety profile, due to the peculiarities of pharmacokinetics and pharmacodynamics of its ingredients; has a combined antimicrobial and antiprotozoal effect, practically without disturbing the quality of normality of the urogenital system and intestines; has a high compliance (is a handy combination for «voluntary compliance, the patient is prescribed the drug regimen»); is available for optimal ten-day course.

It is emphasized that the ease of use (1–2 tablets a day) and affordability make the Ofor a drug of choice in the treatment of sexually transmitted infections, inflammatory and infectious diseases of the pelvis and genitourinary system.

Key words: Ofor, ofloxacin, ornidazole, mixed infection.

REFERENCES

1. Skripchenko NV, Mazaeva EM, Behtereva MK, Ivanova MV. 2013. Osobennosti techeniya meningoentsefalita u rebenka so smeshannoy bakterialnoy infektsiey. Zhurn. infektologii 5;1:103–107.

2. Sindic CJ, Van Antwerpen MP, Goffette S. 2003. Clinical relevance of polymerase chain reaction (PCR) assays and antigen driven immunoblots for the diagnosis of neurological infectious diseases. Brain Res. Bull. 61;3:299–308.

3. Tihomirova OV. 2005. Ostryie kishechnyie infektsii smeshannoy etiologii: osobennosti techeniya i terapii. Terapiya infektsionnyih zabolevaniy u detey: sovremennyie predstavleniya i nereshennyie voprosyi. Materialyi konferentsii NPK:122.

4. Popova OV, Shepeleva IV, Shestakova IV. 2006. Kliniko-immunologicheskaya harakteristika iersinioznoy infektsii. Infektsionnyie bolezni 4;3:51–55.

5. Ivanova VV. 2005. Immunopatogenez infektsionnyih bolezney u detey. Detskie infektsii 4;1:6–11.

6. Yurusova EN. 2009. Kliniko-patogeneticheskaya harakteristika sochetannyih iersinioznyih infektsiy u detey. Avtoref. diss. kand. med. nauk. Vladivostok:154.

7. Letyaeva OI. 2015. Optimizatsiya podhodov k terapii urogenitalnyih mikst-infektsiy u zhenschin reproduktivnogo vozrasta: Tezisyi XXXII nauchno-prakticheskoy konferentsii «Rahmanovskie chteniya». Dermatologiya v Rossii 4;vyip. S1:35.

8. Makovetskaya M. 2013. Ratsionalnaya terapiya urogenitalnyih mikst-infektsiy: v fokuse kombinatsiya tsiprofloksatsin/ornidazol. Zdorov’ya UkraYini HHI storIchchya 19:57.

9. Vremya fiksirovannyih kombinatsiy lekarstvennyih preparatov: ofloksats i ornidazol. Medicus Amicus. 2006. Elektronnyiy resurs. Rezhim dostupa – www.medicusamicus.

10. Tihomirov AL, Yudaev VN, Lubnin DM. 2003. Sovremennyiy algoritm terapii vospalitelnyih zabolevaniy polovoy sferyi. Meditsinskaya panorama 9:40–44.

11. Introduction to Drug Utilization Research. WHO International Working Group for Drug Statistics M 1. ethodology, WHO Collaborating Centre for Drug Statistics Methodology, WHO Collaborating Centre for Drug Utilization Research and Clinical Pharmacological Services. WHO. 2003: 50.

12. Evropeyskie standartyi diagnostiki i lecheniya zabolevaniy, peredavaemyih polovyim putem. K, Med. lIteratura. 2003:264.

13. Про затвердження клінічних протоколів надання медичної допомоги хворим на дерматовенерологічні захворювання. Наказ МОЗ України № 312 від 08.05.2009 р. Электронный ресурс. Режим доступа – www.document.ua

14. Popov SV. 2013. Kombinirovannaya antimikrobnaya terapiya urogenitalnyih infektsiy u muzhchin. Eksperimentalnaya i klinicheskaya urologiya 2:116–120.

15. Mayorov MV, Zhuchenko SI, Zhuperkova EA, Chernyak OL. 2015. Profilaktika posleabortnyih infektsionno-vospalitelnyih oslozhneniy. Meditsinskie aspektyi zdorovya zhenschinyi 4(90):37–42.

16. Kuhar OP, Mamchur DV, Mamchur VI. 2006. Sovremennyie antimikrobnyie preparatyi. Dnepropetrovsk:74.

17. Yakovlev VP. 2000. Mesto ofloksatsina v ambulatornoy praktike: opyit 15-letnego primeneniya. Infektsii i antimikrobnaya terapiya 2;5:154–156.

18. Antibiotiki i protivoinfektsionnyiy immunitet. Pod red. ND Yuschuka, IP Balmasovoy, VN Tsareva. M, Prakticheskaya meditsina. 2012:208–221.

19. Dalhoff A, Shalit I. 2003. Immunomodulatory effects of quinolones. Lancet Infect Dis. 3;7:359–371. http://dx.doi.org/10.1016/S1473-3099(03)00658-3

20. Padeyskaya EN, Yakovlev VP. 1996. Ofloksatsin (Tarivid). Antibakterialnyiy preparat iz gruppyi ftorhinolonov. M:116.

21. Kogan BG, Bondarenko YuG. 2007. Nitroimidazolyi vchera i segodnya: 50 let v borbe s trihomoniazom. Reproduktivnoe zdorove zhenschinyi 5(34):13–19.

22. Padeyskaya EN. 2004. 5-Nitroimidazolyi – antimikrobnyie preparatyi dlya lecheniya bakterialnyih i protozoynyih infektsiy. Consilium medicum 6;1:32–40.

23. Bratzler DW, Houck PM. 2004. Antimicrobial prophylaxis for surgery an advisory statement from national surgical infection prevention project. Clin. Infect. Dis. 38:1706–1715. http://dx.doi.org/10.1086/421095; PMid:15227616

24. Hryanin AA. 2006. Problema vyibora v lechenii trihomonadnoy infektsii: metronidazol ili ornidazol? Klinicheskaya dermatologiya i venerologiya 4:51–53.

25. Inceboz T, Inceboz U, Ozturk S. 2004. Comparative in vitro cytotoxic effects of ornidazole, metronidazole and ciprofloxacin against Trichomonas vaginalis trophozoites. J. Chemother. 16;5:459–462. http://dx.doi.org/10.1179/joc.2004.16.5.459; PMid:15565912

26. Gorpinchenko II, Gurzhenko YuN, Strizhak NS. 2009. Issledovanie klinicheskoy effektivnosti i bezopasnosti preparata Ofor v lechenii mikst-infektsii mochepolovoy sistemyi u muzhchin. Zdorove muzhchinyi 3(30):32–38.

27. Potapov VA, Chuyko VI, Streltsova TR. 2010. Bezopasnost i effektivnost kombinirovannogo preparata OFOR (ofloksatsin ornidazol) v terapii bakterialnogo vaginoza. Elektronnyiy resurs. Rezhim dostupa – www.organosyn.com.ua.

28. Vdovichenko YuP, Himenko MV, Soboleva SI. 2009. Bakterialnyiy vaginoz – sovremennyie podhodyi k lecheniyu i profilaktike retsidivov. Elektronnyiy resurs. Rezhim dostupa – www. organosyn. com. ua.

29. Senchuk AIa, Doskoch IO, Dmitrychenko LM, Ivanenko SV. 2012. Efektyvnist vykorystannia kombinovanoho preparatu OFOR u kompleksnii terapii hostroho sal-pinhooforytu. Zdorove zhenshchynы 9:123–128.

30. Shupenko EN, Shupenko NM. 2013. Opyit primeneniya kombinirovannogo preparata OFOR v kompleksnom lechenii demodekoza i ugrevoy bolezni. UkraYinskiy zhurnal dermatologIYi, venerologIYi, kosmetologIYi 2:41–46.

31. Ofor. Instruktsiya dlya meditsinskogo primeneniya preparata. Elektronnyiy resurs. Rezhim dostupa – www.medguru.ua.

32. Prakticheskoe rukovodstvo po antiinfektsionnoy himioterapii. Pod red. Strachunskiy LS, Belousov YuB, Kozlov SN. M, Borges. 2002:384.